Plant compound blocks action of cancer genes

August 30, 2000



August 31, 2000
-- A plant compound that produces severe neural defects in developing embryos can block the action of mutated genes that produce basal cell skin carcinomas, the most common form of human cancer.

According to researchers at the Howard Hughes Medical Institute (HHMI) at The Johns Hopkins University School of Medicine, the studies in mouse cells suggest that the drug may be used to treat a number of cancers, including medulloblastomas in the brain and rhabdomyosarcomas in muscle. The finding also spotlights the promise of mechanism-based treatment approaches that target specific signaling pathways that are critical to a particular cancer. Conventional chemotherapy, in sharp contrast, kills cancer cells by attacking all proliferating cells -- killing healthy tissue in the process.

In an article in the August 31, 2000, issue of the journal Nature, HHMI investigator Philip A. Beachy and his colleagues reported that the plant compound cyclopamine interferes with the action of the protein encoded by the gene, Smoothened. When Smoothened or its regulator Patched are mutated in skin cells, the cells grow without their normal constraints, and cancer can arise. Smoothened and Patched play a role in sensing the signal produced by Hedgehog, a critical protein in embryonic development.

Beachy's co-authors on the Nature article included Jussi Taipale and colleagues at Hopkins, and HHMI investigator Matthew Scott and his colleagues at Stanford University School of Medicine.

"It had long been known that animals that consumed plants containing cyclopamine suffered severe neural birth defects, including malformations that produced a single cyclopic eye," said Beachy. "And when we knocked out the mouse counterpart of the hedgehog gene, Sonic hedgehog, we saw an effect very much like that produced in animals by cyclopamine. So, that really rang a bell for us."

After initial experiments indicated that cyclopamine did not directly affect the Hedgehog protein, the scientists turned their attention to the two cellular targets that receive signals from Hedgehog -- proteins produced by the genes Smoothened and Patched. While the Smoothened protein switches on cell division, the Patched protein acts as a cellular "brake," or tumor suppressor. Previous studies had shown that Hedgehog switches on cell division by binding to Patched, turning off its normal braking function, and allowing Smoothened to activate cell proliferation.

The scientists' experiments ruled out that cyclopamine might thwart proliferation by activating the Patched protein. They found instead that when they deleted the Patched gene from mouse cells, cyclopamine could still turn off cell division. "Thus, we'd eliminated two red herrings -- that cyclopamine affected either Hedgehog or Patched," said Beachy.

To test whether Smoothened was cyclopamine's target, the scientists first produced mouse cells that expressed high levels of the Smoothened protein. Cyclopamine still suppressed activation of those cells. To investigate the limits of cyclopamine's suppression, the scientists next tested the drug's effects on mouse cells that possessed mutant activated forms of the Smoothened protein that were freed from control by Patched.

These mutant Smoothened-activated cells, the scientists found, proliferated regardless of cyclopamine treatment. Importantly, however, the mutant cells were suppressed by a more potent, synthetic form of cyclopamine.

"All these findings lead us to believe that Smoothened is the target of cyclopamine action, concluded Beachy. "And now that we have evidence that Smoothened is the target, we can further explore whether the interaction is direct or indirect."

Also, said Beachy, further experiments will test the effects of cyclopamine on tumors grown in mice that arise in cells lacking the Patched tumor suppressor.

Howard Hughes Medical Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.